Advent Pharma Limited (As per Prospectus)

	The Common is a Dhamasan tiral same	ware weather the second state
Nature of Business	The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms.	
Major Products	The Company manufactures products in the following three major dosage forms: 1. Bolus Products 2. Powder Products 3. Liquid Products	
Security Trading Code	ADVENT	
BSEC's Consent for IPO	January 11, 2018	
Issue Date of Prospectus	January 15, 2018	
Subscription Open	February 11, 2018	
Subscription Close (Cut-off Date)	February 19, 2018	
Authorized Capital	Tk. 1,000,000,000	
Pre-IPO paid-up Capital	Tk. 486,000,000	
IPO size in shares	20,000,000	
IPO size in Tk. at face value	Tk. 200,000,000	
IPO size in Tk. at offer price	Tk. 200,000,000	
Post IPO Paid-up Capital	Tk. 686,000,000	
Face Value per share	Tk. 10.00	
Offer Price per share	Tk. 10.00	
Market Lot (Shares)	500	
Foreign Currency required for NRB and Foreign Applicants (per lot)	USD 60.65 or GBP 44.25 or EUR 49.96	
Use of IPO Proceeds	Acquisition of Machineries and Equipments	81,430,800 (40.72%)
	Construction of Building and other Civil Works	100,069,200 (50.03%)
	IPO Expenses	18,500,000 (9.25%)
	Total	200,000,000 (100.00%)
NAV per share	Tk. 12.45 as at June 30, 2017	
Earnings per Share (Basic)	Tk. 1.49 for the year ended on June 30, 2017	
Issue Manager	Imperial Capital Limited, Alpha Capital Management Limited and CAPM Advisory Limited	
Auditor	Mahfel Huq & Co.	
Website	www.adventpharmabd.com	
	1	